Determining the optimal dose in the development of anticancer agents
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Determining the optimal dose in the development of anticancer agents
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 11, Issue 5, Pages 272-281
Publisher
Springer Nature
Online
2014-03-25
DOI
10.1038/nrclinonc.2014.40
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors
- (2013) N. Yamamoto et al. ANNALS OF ONCOLOGY
- Evaluation of Food Effect on Pharmacokinetics of Vismodegib in Advanced Solid Tumor Patients
- (2013) M. R. Sharma et al. CLINICAL CANCER RESEARCH
- The Effect of St John’s Wort on the Pharmacokinetics of Docetaxel
- (2013) Andrew K. L. Goey et al. CLINICAL PHARMACOKINETICS
- Playing Russian Roulette With Tyrosine Kinase Inhibitors
- (2013) R Z Szmulewitz et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Building a Personalized Medicine Infrastructure at a Major Cancer Center
- (2013) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Advancing Precision Medicine for Prostate Cancer Through Genomics
- (2013) Sameek Roychowdhury et al. JOURNAL OF CLINICAL ONCOLOGY
- AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
- (2013) Luca Gianni et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- What does a modified-Fibonacci dose-escalation actually correspond to?
- (2012) Nicolas Penel et al. BMC Medical Research Methodology
- A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients
- (2012) K. Eechoute et al. CLINICAL CANCER RESEARCH
- Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy
- (2012) A.-J. M. de Graan et al. CLINICAL CANCER RESEARCH
- Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?
- (2012) N R Budha et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Cancer pharmacogenomics: strategies and challenges
- (2012) Heather E. Wheeler et al. NATURE REVIEWS GENETICS
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
- (2011) A C Mita et al. BRITISH JOURNAL OF CANCER
- Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients
- (2011) Naoto Takahashi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients
- (2011) Ninh M. La-Beck et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Flushing Oral Oncology Drugs Down the Toilet
- (2011) Mark J. Ratain JOURNAL OF CLINICAL ONCOLOGY
- Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study
- (2011) Julie R. Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Moving towards dose individualization of tyrosine kinase inhibitors
- (2010) Heinz-Josef Klümpen et al. CANCER TREATMENT REVIEWS
- Drug Transporters and Imatinib Treatment: Implications for Clinical Practice
- (2010) K. Eechoute et al. CLINICAL CANCER RESEARCH
- Dose-escalation models for combination phase I trials in oncology
- (2010) Paul Hamberg et al. EUROPEAN JOURNAL OF CANCER
- Castration-Dependent Pharmacokinetics of Docetaxel in Patients With Prostate Cancer
- (2010) Ryan M. Franke et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients
- (2010) JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
- (2010) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of the Proton Pump Inhibitor Esomeprazole on the Oral Absorption and Pharmacokinetics of Nilotinib
- (2010) Ophelia Q. P. Yin et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations
- (2010) Wee-Lee Yeo et al. Journal of Thoracic Oncology
- Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker
- (2010) Daniel Binder et al. MEDICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of a proton pump inhibitor on the pharmacokinetics of imatinib
- (2009) Merrill J. Egorin et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The Price of Success: Cost-Effectiveness of Molecularly Targeted Agents
- (2009) S Sleijfer et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Phase I Drug Combination Trial Design: Walking the Tightrope
- (2009) Paul Hamberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers
- (2009) Andrew N. Hughes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects
- (2009) Timothy Eley et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Dose Escalation Methods in Phase I Cancer Clinical Trials
- (2009) Christophe Le Tourneau et al. JNCI-Journal of the National Cancer Institute
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
- (2008) E. Jabbour et al. BLOOD
- Effect of antacid on imatinib absorption
- (2008) Brian A. Sparano et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The biological and clinical role of drug transporters at the intestinal barrier
- (2008) Roos L. Oostendorp et al. CANCER TREATMENT REVIEWS
- Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC
- (2008) N. van Erp et al. CLINICAL CANCER RESEARCH
- Lifestyle habits as a contributor to anti-cancer treatment failure
- (2008) Floris A. de Jong et al. EUROPEAN JOURNAL OF CANCER
- ‘No risk, no fun’: Challenges for the oncology phase I clinical trial time-performance
- (2008) Jaap Verweij EUROPEAN JOURNAL OF CANCER
- Will We Ever Be Ready for Blood Level–Guided Therapy?
- (2008) Christine M. Walko et al. JOURNAL OF CLINICAL ONCOLOGY
- Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer
- (2008) Erick Gamelin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
- (2008) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- (2008) Manuela Schmidinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- Drug Insight: gastrointestinal stromal tumors (GIST)—the solid tumor model for cancer-specific treatment
- (2008) Stefan Sleijfer et al. Nature clinical practice. Oncology
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started